About
About J. B. Chemicals & Pharmaceuticals Limited
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
Research context
J. B. Chemicals & Pharmaceuticals Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
J. B. Chemicals & Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 51.7% above its 200 day moving average.
From a valuation standpoint, the stock is 2.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 4.9.
J. B. Chemicals & Pharmaceuticals Limited's total revenue rose by 27.9% to $5B since the same quarter in the previous year.
Its net income has increased by 132.5% to $2B since the same quarter in the previous year.
Finally, its free cash flow fell by 56.9% to $732M since the same quarter in the previous year.
Based on the above factors, J. B. Chemicals & Pharmaceuticals Limited gets an overall score of 3/5.